

Antonio
RUSSO

Russo A, Bazan V, Plaja S, Leonardi P, Bazan P. Patterns of DNA-ploidy in operable colorectal carcinoma: a prospective study of 100 cases.
J Surg Oncol. 1991 Sep;48(1):4-10.

Russo A, Bazan V, Plaja S, Cajozzo M, Bazan P. Flow cytometric DNA analysis of hepatic tumours on ultrasound-guided fine-needle aspirates.
J Surg Oncol. 1992 Sep;51(1):26-32.

Campanella R, Russo A, Plaja S, Bazan V, Pavone C, Corselli G, Pavone-Macaluso M. Study of cellular DNA content by flow cytometry in primary bladder carcinomas. Significance of monoclonal and multiclonal varieties of DNA aneuploidy.
Eur Urol. 1992;21(1):58-63.

Gebbia V, Gebbia N, Russo A, Testa A, Valenza R, Zerillo G, Ingria F, Spadafora G, Rausa L. Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
Anticancer Drugs. 1992 Aug;3(4):347-9.

Gebbia V, Russo A, Gebbia N, Rausa L, Ingria F, Spatafora G, Zerillo G, Cimino A, Pastorello T, Ferrara P, et al. High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
J Cancer Res Clin Oncol. 1992;118(6):458-62.

Palmeri S, Gebbia V, Russo A, Gebbia N, Rustum Y, Rausa L. Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma.
Cancer Invest. 1992;10(6):497-504.

Russo A, Gebbia V, Palmeri S, Geraci P, Maneschi F, Guarnieri G, Carollo F, Leonardi V, Meli M, Gebbia N, et al. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
Eur J Gynaecol Oncol. 1993;14(3):228-33.

La Farina M, Alberti M, Russo A, Bazan V, Grasso G, Romancino D, Bazan P, Albanese I. Optimization of RNA and DNA purification procedures from human colorectal carcinomas.
Anticancer Res. 1993 Sep-Oct;13(5A):1485-90.

Marrazzo A, Russo A, Bazan V, Taormina P, Lupo F, Bazan P. Immunocytochemical determination of estrogen and progesterone receptors and flow cytometric DNA analysis of breast cancer on fine needle aspirates.
Anticancer Res. 1993 Nov-Dec;13(6B):2435-40.

Tomasino RM, Russo A, Bazan V, Morello V, Tralongo V, Nagar C, Salvato M, Taormina P, Marrazzo A, Nuara R, et al. Evaluation of integrated morpho-biological indicators in breast cancer.
In Vivo. 1993 Nov-Dec;7(6B):601-5.

Albanese I, Alberti M, Bazan V, Russo A, Baiamonte S, Migliavacca M, Bazan P, La Farina M. Structural analysis of c-myc in human sporadic colorectal carcinomas.
Anticancer Res. 1994 May-Jun;14(3A):1103-6.

Russo A, Bazan V, Morello V, Tralongo V, Nagar C, Nuara R, Dardanoni G, Bazan P, Tomasino RM. Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors. Prognostic role in breast cancer.

Anal Quant Cytol Histol. 1994 Oct;16(5):365-74.

Tumminello FM, Gebbia N, Pizzolanti G, Russo A, Bazan V, Leto G. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report.

Oncology. 1995 May-Jun;52(3):237-42.

Russo A, Bazan V, Gebbia N, Pizzolanti G, Tumminello FM, Dardanoni G, Ingoia F, Restivo S, Tomasino RM, Leto G. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance.

Cancer. 1995 Nov 15;76(10):1757-64.

Daniele E, Tralongo V, Morello V, Nagar C, Russo A, Bazan V, Dardanoni G, Ciotta S, Nuara R, Tomasino RM. Pleomorphic adenoma and adenoid-cystic carcinoma of salivary glands: immunohistochemical assessment of proliferative activity in comparison with flow-cytometric study.

Cell Prolif. 1996 Mar;29(3):153-62.

Tomasino RM, Bazan V, Daniele E, Nuara R, Morello V, Tralongo V, Leto G, Russo A. Biological characterization of laryngeal squamous-cell carcinoma.

Anticancer Res. 1996 Jul-Aug;16(4B):2257-67.

Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, Bazan P, Modica G, Albanese I, La Farina M, Tomasino RM, Russo A. Flow cytometric S-phase fraction as an independent prognostic indicator in colorectal liver metastases.

Eur J Histochem. 1997;41 Suppl 2:137-8.

Palmeri S, Meli M, Danova M, Bernardo G, Leonardi V, Dastoli G, Rausa L, Russo A, Filippelli G, Palmieri G, Russo A, Della Vittoria Scarpati M, Lo Russo V, Di Lauro L, Colucci G, Bruni G, Piazzi M, Gebbia N, Spada S. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.

J Cancer Res Clin Oncol. 1998;124(3-4):191-8.

La Farina M, Maturi N, Stira S, Russo A, Bazan V, Albanese I. Direct identification of each specific mutation in codon 12 and 13 of *ki-ras2* by SSCP analysis.

Biochem Biophys Res Commun. 1998 May 29;246(3):813-5.

Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, Modica G, Bazan P, Albanese I, La Farina M, Tomasino RM. Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases.

Cell Prolif. 1998 Jun-Aug;31(3-4):139-53.

Alderisio M, Cenci M, Valli C, Russo A, Bazan V, Dardanoni G, Cucciarre S, Carreca I, Macaluso MP, Tomasino RM, Vecchione A. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.

Anticancer Res. 1998 Nov-Dec;18(6A):4225-30.

Russo A, Bazan V, Migliavacca M, Zanna I, Tubiolo C, Tumminello FM, Dardanoni G, Cajozzo M, Bazan P, Modica G, Latteri M, Tomasino RM, Colucci G, Gebbia N, Leto G. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma.
Clin Cancer Res. 2000 Jan;6(1):178-84.

Russo A, Zanna I, Tubiolo C, Migliavacca M, Bazan V, Latteri MA, Tomasino RM, Gebbia N. Hereditary common cancers: molecular and clinical genetics.
Anticancer Res. 2000 Nov-Dec;20(6C):4841-51.

Russo A, Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Latteri F, Valerio MR, Pantuso G, Morello V, Dardanoni G, Latteri MA, Colucci G, Tomasino RM, Gebbia N. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GDIM) prospective study.
Cancer. 2001 Jul 15;92(2):294-302.

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urošević N. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.
Br J Cancer. 2001 Sep 1;85(5):692-6.

Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Amato A, Calò V, Dardanoni G, Morello V, La Farina M, Albanese I, Tomasino RM, Gebbia N, Russo A. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
J Cell Physiol. 2002 May;191(2):237-46.

Bazan V, Zanna I, Migliavacca M, Sanz-Casla MT, Maestro ML, Corsale S, Macaluso M, Dardanoni G, Restivo S, Quintela PL, Bernaldez R, Salerno S, Morello V, Tomasino RM, Gebbia N, Russo A. Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma.
J Cell Physiol. 2002 Sep;192(3):286-93.

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.
Ann Oncol. 2002 Sep;13(9):1438-46.

Russo A, Migliavacca M, Zanna I, Valerio MR, Latteri MA, Grassi N, Pantuso G, Salerno S, Dardanoni G, Albanese I, La Farina M, Tomasino RM, Gebbia N, Bazan V. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up. *Cancer Epidemiol Biomarkers Prev.* 2002 Nov;11(11):1322-31.

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Corsale S, Calò V, Amato A, Cammareri P, Latteri F, Grassi N, Fulfaro F, Porcasi R, Morello V, Nuara RB, Dardanoni G, Salerno S, Valerio MR, Dusonchet L, Gerbino A, Gebbia N, Tomasino RM, Russo A. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. *J Cancer Res Clin Oncol.* 2002 Dec;128(12):650-8.

Macaluso M, Cinti C, Russo G, Russo A, Giordano A. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. *Oncogene.* 2003 Jun 5;22(23):3511-7.

Fulfaro F, Valerio MR, Badalamenti G, Gebbia N, Russo A. Antitubercular drug combinations with ifosfamide: an update. *Oncology.* 2003;65 Suppl 2:21-30.

Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. *J Cell Physiol.* 2003 Nov;197(2):157-68. Review.

Migliavacca M, Ottini L, Bazan V, Agnese V, Corsale S, Macaluso M, Lupi R, Dardanoni G, Valerio MR, Pantuso G, Di Fede G, Tomasino RM, Gebbia N, Mariani-Costantini R, Russo A. TP53 in gastric cancer: mutations in the L3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. *J Cell Physiol.* 2004 Sep;200(3):476-85.

Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, Colomba P, Tagliavia M, La Farina M. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. *Biochem Biophys Res Commun.* 2004 Dec 17;325(3):784-91.

Bazan V, La Rocca G, Corsale S, Agnese V, Macaluso M, Migliavacca M, Gregorio V, Cascio S, Sisto PS, Di Fede G, Buscemi M, Fiorentino E, Passantino R, Morello V, Tomasino RM, Russo A. Laser pressure catapulting (LPC): optimization LPC-system and genotyping of colorectal carcinomas. *J Cell Physiol.* 2005 Feb;202(2):503-9.

Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. *Ann Oncol.* 2005 May;16 Suppl 4:iv44-iv49.

Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.

Ann Oncol. 2005 May;16 Suppl 4:iv50-iv55.

Russo A, Corsale S, Cammareri P, Agnese V, Cascio S, Di Fede G, Macaluso M, Bazan V. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.

J Cell Physiol. 2005 Sep;204(3):742-9.

Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A, Intrivici C, Gebbia N. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.

J Chemother. 2005 Oct;17(5):555-9.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.

J Clin Oncol. 2005 Oct 20;23(30):7518-28.

Russo A, Corsale S, Agnese V, Macaluso M, Cascio S, Bruno L, Surmacz E, Dardanoni G, Valerio MR, Vieni S, Restivo S, Fulfaro F, Tomasino RM, Gebbia N, Bazan V. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.

J Cell Physiol. 2006 Jan;206(1):181-8.

Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85.

Calò V, Agnese V, Gargano G, Corsale S, Gregorio V, Cascio S, Cammareri P, Bruno L, Augello C, Gullo A, Sisto PS, Badalamenti G, Valerio MR, Napoli L, Gebbia N, Bazan V, Russo A. A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.

Breast Cancer Res Treat. 2006 Mar;96(1):97-100.

Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J,

Russo A, Sulkowski S, Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.

Clin Cancer Res. 2006 Mar 1;12(5):1447-53.

Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

Ann Oncol. 2006 May;17(5):835-41.

Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, Cascio S, Corsale S, Calò V, Gullo A, Passantino R, Gargano G, Bruno L, Rinaldi G, Morello V, Gerbino A, Tomasino RM, Macaluso M, Surmacz E, Russo A. TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.

J Cell Physiol. 2006 Jun;207(3):654-9.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di Fede G, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capellá GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, Allen-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
Ann Oncol. 2006 May;17(5):842-7.

Rocco A, Caruso R, Toracchio S, Rigoli L, Verginelli F, Catalano T, Neri M, Curia MC, Ottini L, Agnese V, Bazan V, Russo A, Pantuso G, Colucci G, Mariani-Costantini R, Nardone G. Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Ann Oncol. 2006 Jun;17 Suppl 7:vii103-vii108.

Russo A, Terrasi M, Agnese V, Santini D, Bazan V. Apoptosis: a relevant tool for anticancer therapy.
Ann Oncol. 2006 Jun;17 Suppl 7:vii115-vii123.

Agnese V, Corsale S, Calò V, Augello C, Bruno L, Calcara D, Crosta A, Rodolico V, Rinaldi G, Cicero G, Latteri F, Agrusa A, Morello V, Adamo V, Altavilla G, Di Fede G, Fiorentino E, Grassi N, Latteri MA, Valerio MR, Tomasino RM, Colucci G, Bazan V, Russo A. Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Ann Oncol. 2006 Jun;17 Suppl 7:vii137-vii141.

Augello C, Bruno L, Bazan V, Calò V, Agnese V, Corsale S, Cascio S, Gargano G, Terrasi M, Barbera F, Fricano S, Adamo B, Valerio MR, Colucci G, Sumarcz E, Russo A. Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Ann Oncol. 2006 Jun;17 Suppl 7:vii30-vii33.

Gargano G, Agnese V, Calò V, Corsale S, Augello C, Bruno L, La Paglia L, Gullo A, Ottini L, Russo A, Fulfaro F, Rinaldi G, Crosta A, Cicero G, Majorana O, Palmeri L, Cipolla C, Agrusa A, Gulotta G, Morello V, Di Fede G, Adamo V, Colucci G, Tomasino RM, Valerio MR, Bazan V, Russo A. Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Ann Oncol. 2006 Jun;17 Suppl 7:vii41-vii45.

Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Ann Oncol. 2006 Jun;17(suppl_7):vii68-vii72.

Bazan V, Bruno L, Augello C, Agnese V, Calò V, Corsale S, Gargano G, Terrasi M, Schirò V, Di Fede G, Adamo V, Intrivici C, Crosta A, Rinaldi G, Latteri F, Dardanoni G, Grassi N, Valerio MR, Colucci G, Macaluso M, Russo A. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

Ann Oncol. 2006 Jun;17 Suppl 7:vii84-vii90.

Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, Bazan V, Agnese V, Esposito DL, De Lellis L, Semeraro D, Colucci G, Hormazdi M, Rakhshani N, Cama A, Piantelli M, Iacobelli S, Russo A, Mariani-Costantini R. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin.

Ann Oncol. 2006 Jun;17 Suppl 7:vii91-vii96.

Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A. Patterns of genomic instability in gastric cancer: clinical implications and perspectives.

Ann Oncol. 2006 Jun;17(suppl_7):vii97-vii102.

Cascio S, Bartella V, Garofalo C, Russo A, Giordano A, Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells.

J Biol Chem. 2007 Feb 9;282(6):3498-506.

Perrone G, Vincenzi B, Zagami M, Santini D, Panteri R, Flammia G, Verzì A, Lepanto D, Morini S, Russo A, Bazan V, Tomasino RM, Morello V, Tonini G, Rabitti C. Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.

Mod Pathol. 2007 Mar;20(3):344-51.

Gargano G, Calcara D, Corsale S, Agnese V, Intrivici C, Fulfaro F, Pantuso G, Cajozzo M, Morello V, Tomasino RM, Ottini L, Colucci G, Bazan V, Russo A. Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

Ann Oncol. 2007 Jun;18 Suppl 6:vi103-9.

Agnese V, Cabibi D, Calcara D, Terrasi M, Pantuso G, Fiorentino E, Intrivici C, Colucci G, Aragona F, Gebbia N, Bazan V, Russo A. Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.

Ann Oncol. 2007 Jun;18 Suppl 6:vi110-5.

Koda M, Sulowska M, Kanczuga-Koda L, Cascio S, Colucci G, Russo A, Surmacz E, Sulkowski S. Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer.

Ann Oncol. 2007 Jun;18 Suppl 6:vi116-9.

Badalamenti G, Rodolico V, Fulfaro F, Cascio S, Cipolla C, Cicero G, Incorvaia L, Sanfilippo M, Intrivici C, Sandonato L, Pantuso G, Latteri MA, Gebbia N, Russo A. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features.

Ann Oncol. 2007 Jun;18 Suppl 6:vi136-40.

Campisi G, Di Fede O, Musciotto A, Lo Casto A, Lo Muzio L, Fulfaro F, Badalamenti G, Russo A, Gebbia N. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis.

Ann Oncol. 2007 Jun;18 Suppl 6:vi168-72.

Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. The role of Aurora-A inhibitors in cancer therapy.

Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52.

Manna G, Foddai E, Di Maggio MG, Pace F, Colucci G, Gebbia N, Russo A. Emotional expression and coping style in female breast cancer.

Ann Oncol. 2007 Jun;18 Suppl 6:vi77-80.

Sisci D, Morelli C, Cascio S, Lanzino M, Garofalo C, Reiss K, Garcia M, Russo A, Andò S, Surmacz E. The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships.

Ann Oncol. 2007 Jun;18 Suppl 6:vi81-5.

Veschi S, Aceto G, Scioletti AP, Gatta V, Palka G, Cama A, Mariani-Costantini R, Battista P, Calò V, Barbera F, Bazan V, Russo A, Stuppia L. High prevalence of BRCA1 deletions in BRCA1-positive patients with high carrier probability.

Ann Oncol. 2007 Jun;18 Suppl 6:vi86-92.

Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A. Founder mutations in BRCA1 and BRCA2 genes.

Ann Oncol. 2007 Jun;18 Suppl 6:vi93-8.

Russo A, Calò V, Augello C, Bruno L, Agnese V, Schirò V, Barbera F, Cascio S, Foddai E, Badalamenti G, Intrivici C, Cajozzo M, Gulotta G, Surmacz E, Colucci G, Gebbia N, Bazan V. 4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

Ann Oncol. 2007 Jun;18 Suppl 6:vi99-102.

Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A, Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha.

Oncogene. 2007 Jul 23

Russo A, Calò V, Agnese V, Bruno L, Corsale S, Augello C, Gargano G, Barbera F, Cascio S, Intrivici C, Rinaldi G, Gulotta G, Macaluso M, Surmacz E, Giordano A, Gebbia N, Bazan V. BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.

Breast Cancer Res Treat. 2007 Nov;105(3):267-76.

Russo A, Fratto ME, Bazan V, Schirò V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

Expert Opin Ther Targets. 2007 Dec;11(12):1571-1586.